Cinctive Capital Management Reduces Stake in CG Oncology

Institutional investor cuts holdings in biopharmaceutical company by over 60%

Mar. 17, 2026 at 8:09am

Got story updates? Submit your updates here. ›

Cinctive Capital Management LP has reduced its stake in CG Oncology, Inc. (NASDAQ:CGON) by 61.6% during the third quarter, according to a recent SEC filing. The institutional investor now owns 32,558 shares of the company's stock, down from 84,856 shares previously.

Why it matters

CG Oncology is a clinical-stage biopharmaceutical company focused on developing novel antibody-based immunotherapies for solid tumor cancers. Changes in institutional ownership can signal shifts in investor sentiment and impact the company's access to capital markets.

The details

According to the 13F filing, Cinctive Capital Management sold 52,298 shares of CG Oncology stock during the third quarter. The firm's remaining 32,558 shares were worth $1.31 million at the end of the reporting period. Other major investors in CG Oncology include PNC Financial Services Group, CWM LLC, and the Police & Firemen's Retirement System of New Jersey.

  • Cinctive Capital Management filed its 13F report for the third quarter of 2026.

The players

Cinctive Capital Management LP

An institutional investment firm that has reduced its stake in CG Oncology by over 60%.

CG Oncology, Inc.

A clinical-stage biopharmaceutical company focused on developing novel antibody-based immunotherapies for solid tumor cancers.

Got photos? Submit your photos here. ›

The takeaway

The significant reduction in Cinctive Capital Management's position in CG Oncology could signal a shift in investor sentiment around the company's prospects, though the reasons behind the sell-off are not entirely clear. This change in institutional ownership bears watching as CG Oncology continues to advance its pipeline of cancer immunotherapies.